[1]张 皓.茚达特罗联合盐酸溴己新治疗支气管扩张伴感染的临床疗效及对气道炎性反应缓解作用的影响[J].医学信息,2023,36(11):106-109.[doi:10.3969/j.issn.1006-1959.2023.11.020]
　ZHANG Hao.Clinical Efficacy of Indacaterol Combined with Bromohexine Hydrochloride in the Treatment of Bronchiectasis with Infection and its Effect on the Alleviation of Airway Inflammatory Response[J].Journal of Medical Information,2023,36(11):106-109.[doi:10.3969/j.issn.1006-1959.2023.11.020]
点击复制

茚达特罗联合盐酸溴己新治疗支气管扩张伴感染的临床疗效及对气道炎性反应缓解作用的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年11期
页码:
106-109
栏目:
论著
出版日期:
2023-06-01

文章信息/Info

Title:
Clinical Efficacy of Indacaterol Combined with Bromohexine Hydrochloride in the Treatment of Bronchiectasis with Infection and its Effect on the Alleviation of Airway Inflammatory Response
文章编号:
1006-1959（2023）11-0106-04
作者:
张 皓
（佳木斯大学附属第一医院内科，黑龙江 佳木斯 154000）
Author(s):
ZHANG Hao
(Department of Internal Medicine,the First Affiliated Hospital of Jiamusi University,Jiamusi 154000,Heilongjiang,China)
关键词:
茚达特罗; 盐酸溴己新; 支气管扩张伴感染; 气道炎性反应
Keywords:
Indacterol; Bromohexine hydrochloride; Bronchiectasis with infection; Airway inflammation
分类号:
R562.22
DOI:
10.3969/j.issn.1006-1959.2023.11.020
文献标志码:
A
摘要:
目的 研究茚达特罗联合盐酸溴己新治疗支气管扩张伴感染临床疗效及对气道炎性反应缓解作用的影响。方法 选取2021年1月-2023年1月在我院诊治的60例支气管扩张伴感染患者为研究对象，采用随机数字表法分为对照组（30例）和观察组（30例），对照组采用盐酸溴己新治疗，观察组在对照组基础上联合茚达特罗治疗，比较两组临床疗效、临床症状缓解时间、痰液炎性指标[白细胞（WBC）、C反应蛋白（CRP）、中性粒细胞]、肺功能指标[用力肺活量（FVC）、第1 s用力呼气容积（FEV1）、FEV1/FVC、最大呼气流量（PEF）]以及不良反应发生率。结果 观察组治疗总有效率为90.00%，高于对照组的76.67%（P＜0.05）；观察组咳嗽、湿啰音、胸痛、口干、发热缓解时间均短于对照组（P＜0.05）；两组治疗后WBC、CRP、中性粒细胞水平均低于治疗前，且观察组低于对照组（P＜0.05）；治疗后观察组FVC、FEV1、FEV1/FVC、PEF均高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 茚达特罗联合盐酸溴己新治疗支气管扩张伴感染具有理想的效果，可快速缓解临床症状，减轻气道炎性反应，促进肺功能指标恢复，且不会增加不良反应，有利于患者的快速康复，值得临床应用。
Abstract:
Objective To investigate the clinical efficacy of indacterol combined with bromohexine hydrochloride in the treatment of bronchiectasis with infection and its effect on the alleviation of airway inflammatory response.Methods From January 2021 to January 2023, 60 patients with bronchiectasis and infection diagnosed and treated in our hospital were selected as the research objects. They were divided into control group (30 patients) and observation group (30 patients) by random number table method. The control group was treated with bromhexine hydrochloride, and the observation group was treated with indacaterol on the basis of the control group. The clinical efficacy, remission time of clinical symptoms, sputum inflammatory indexes [white blood cell (WBC), C-reactive protein (CRP), neutrophils], lung function indexes [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC, maximum expiratory flow (PEF)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 90.00%, which was higher than 76.67% in the control group (P<0.05). The remission time of cough, moist rale, chest pain, dry mouth and fever in the observation group were shorter than those in the control group (P<0.05). After treatment, the levels of WBC, CRP and neutrophils in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). After treatment, FVC, FEV1, FEV1/FVC and PEF in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Indacaterol combined with bromhexine hydrochloride has a ideal effect in the treatment of bronchiectasis with infection, which can quickly relieve clinical symptoms, reduce airway inflammation, promote the recovery of lung function indicators, and will not increase adverse reactions. Meanwhile, it is conducive to the rapid recovery of patients and is worthy of clinical application.

参考文献/References:

[1]张玉.自拟宣肺化痰方合痰热清注射液治疗支气管扩张症急性加重期痰热郁肺证疗效及对血气分析指标、炎症因子的影响[J]. 现代中西医结合杂志,2019,28(20):2250-2253.[2]金苗.小儿肺炎患儿机体免疫功能特点和使用肺力咳合剂的改善价值研究[J].中国妇幼保健,2020,35(16):3024-3026.[3]王剑.肺力咳合剂联合氨茶碱治疗儿童支气管哮喘的疗效观察[J].现代药物与临床,2017,32(3):436-438.[4]徐琳,路苹,姚红梅,等.支气管扩张症合并感染患者血清人分泌型磷脂酶A2-X表达情况及其与炎性指标的相关性研究[J].中国全科医学,2020,23(24):3034-3039.[5]罗金海,张建华,刘勇,等.血凝酶联合支气管肺泡灌洗对支气管扩张合并咯血患者肺功能、气道炎症及预后的影响[J].海南医学,2020,31(5):570-573.[6]申永春,文富强.《慢性气道炎症性疾病气道黏液高分泌管理中国专家共识》解读[J].中国实用内科杂志,2016,36(2):131-132,136.[7]许惠莲,郭寿贵,吴欣宇.肺力咳合剂联合盐酸溴己新对支气管扩张伴感染患者临床症状及气道炎性反应的缓解作用研究[J].世界中西医结合杂志,2021,16(4):705-709.[8]Duffy SP,Criner GJ.Chronic obstructive pulmonary disease[J].Med Clin North Am,2019,103(3):453-461.[9]陈勇,谭经福,廖振辉,等.纤维支气管镜肺泡灌洗联合依替米星局部给药治疗支气管扩张并感染的临床疗效[J].疑难病杂志,2018,17(2):133-136.[10]孙孝魁.清肺宁络饮治疗支气管扩张症急性加重期(痰热壅肺证)患者的临床疗效观察及对血清NE/TNF-α水平的影响[D].合肥:安徽中医药大学,2021.[11]邱磊,杨铭,张少言,等.基于现代文献和数据挖掘探讨支气管扩张症的中医组方用药规律[J].结核与肺部疾病杂志,2020,1(4):233-239.[12]方婵丹,陈池云,江明阳,等.支气管扩张症患者肺通气功能障碍及肺气肿的高危因素分析[J].全科医学临床与教育,2020,18(12):1064-1067,1075.[13]刘盈,孔志斌,李虹,等.临床药师参与支气管扩张伴血流感染患者抗菌药物治疗的用药分析[J].山西医科大学学报,2017,48(4):401-403.[14]Congleton J.COPD:how many asthmatics does it take to make an impact?[J].Drug Ther Bull,2019,57(2):18.[15]汝触会,陈爱凤,何飞,等.支气管扩张症合并非结核分枝杆菌感染患者血清和肽素、分泌型磷脂酶A2-X及致炎-抑炎因子谱的变化[J].解放军医学杂志,2021,46(11):1098-1103.[16]周璇.自拟清肺化痰汤加减联合常规西药治疗成人痰热壅肺型支气管扩张临床疗效观察[J].四川中医,2019,37(2):91-93.[17]刘洁静,冯京帅,李霞,等.清肺化痰汤合千金苇茎汤加减对支气管扩张患者FEV1、FVC及PEF水平的影响[J].陕西中医,2020,41(9):1221-1224.[18]吴伟,张倩,李勤.茚达特罗格隆溴铵联合乙酰半胱氨酸治疗慢性阻塞性肺疾病的临床效果[J].中国老年学杂志,2022,42(4):1623-1628.[19]苏连杰.阿地溴铵联合茚达特罗治疗慢性阻塞性肺疾病的临床疗效及对患者免疫功能的影响[J].吉林医学,2022,15(10):24-26.[20]陈刚,徐永芳,徐长青,等.哌拉西林/他唑巴坦联合依替米星治疗支气管扩张患者感染疗效的分析[J].中华医院感染学杂志,2017,26(9):1970-1972.

更新日期/Last Update: 1900-01-01